Victoza liraglutide: Phase IIIa started

Novo Nordisk disclosed in its 1H11 earnings that in June it began a double-blind, placebo-controlled, international Phase IIIa trial to evaluate 1.8 and 3 mg subcutaneous liraglutide once daily for 56...